Jubilant Pharmova: Financial Results
Jubilant Pharmova (JUBLPHARMA) filed a disclosure titled "Financial Results". The company is valued at about ₹15,729 crore.
What happened
Jubilant Pharmova (JUBLPHARMA) filed a disclosure with the exchanges on 13 November 2026 at 08:11 PM titled "Financial Results".
From the filing: "Jubilant Pharmova Limited has informed the Exchange regarding a press release dated November 13, 2026, titled "Press Release on financial Results"."
Company snapshot
Jubilant Pharmova is a small-cap company in the Healthcare sector, with a market value of about ₹15,729 crore.
The stock last traded at ₹987.5, against a 52-week range of ₹786.1–₹1,162 (15.0% below the high).
Before this filing the shares had moved +3.9% over the month and +10.9% over three months. Average daily turnover over the last 20 sessions was about ₹10.56 crore.
Promoters held 47.68% at the end of Q1 FY27; 6.58% of promoter shares were pledged. Foreign institutions owned 15.87% and domestic institutions 12.40%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 1,901 | 102.9 | 6.49 |
| Q2 FY26 | 1,966 | 120.3 | 7.59 |
| Q3 FY26 | 2,123 | 55.9 | 3.52 |
| Q4 FY26 | 2,290 | 119.4 | 7.55 |
| Q1 FY27 | 2,229 | 56.5 | 3.57 |
What history shows
This is not the company's first results disclosure: BCEIE has 1 earlier filing of this kind on record since May 2026.
Across 300 similar disclosures by other Healthcare companies, shares moved +1.4% on average the next day and +3.0% over five days; 58% of them rose the next day.
Market-wide, 11,788 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 43% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 13 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- Jubilant Pharmova Q1 Revenue Rises 17% to ₹2,229 Crore
- Jubilant Pharmova allots ₹800 crore NCDs at 8.50% coupon
- Jubilant Pharmova raises $84.6M in debut local bond issue
- Jubilant Pharmova clears ₹800 crore NCD fundraise | Tap to know more | Inshorts
- Jubilant Pharmova Says Jubilant Therapeutics Announces Oral Presentation Of Preliminary Phase 1 Clinical Data For JBI-802
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.